Choosing the first treatment for advanced bladder cancer
Part of Cancer clinical trials.
This study looks at the different ways doctors choose the first treatment for patients whose urothelial cancer has spread. It aims to understand what factors influence that choice, which could help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have urothelial cancer that has spread to other parts of the body (metastatic).
- You have started your first treatment for this metastatic cancer since October 2024.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
This trial tests whether removing the primary bladder tumor and any remaining metastatic spots after initial medication (enfortumab-vedotin) improves outcomes for people with a limited number of metastases (5 or fewer). It is for those whose cancer has responded or stabilized on treatment.
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial tests whether adding targeted radiation therapy to standard drug treatment can help people with urothelial cancer that has spread to a few spots (up to 3 outside the brain). If you are starting your first or second round of systemic therapy, this study may be an option.
This study looks at how well the combination of enfortumab vedotin and pembrolizumab (EV+P) works as the first treatment for people with advanced or metastatic bladder cancer or other rare urinary tract tumors. By reviewing medical records, researchers hope to learn more about the benefits of this therapy.
Hear when a new Metastatic Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.